Developing new tools to modify immune cells for better disease treatment
TR&D Project 2
This study is working on new tiny tools that help change how your immune cells work, which could lead to better treatments for conditions like cancer and autoimmune diseases, and these tools will be shared with other scientists to help everyone learn more about the immune system.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11134619 on NIH RePORTER |
What this research studies
This research focuses on creating innovative nanoimmunomaterial tools designed to enhance the ability to modify immune cells both outside and inside the body. By engineering nanoparticles and biomaterials, the project aims to improve the delivery of genetic materials specifically to immune cells, such as dendritic cells, macrophages, and T cells. The goal is to either stimulate or suppress immune responses to specific antigens, which could have significant implications for treating conditions like cancer and autoimmune diseases. The tools developed will be shared with other researchers to advance the field of immunology and bioengineering.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancer or autoimmune conditions who may benefit from advanced immunotherapy techniques.
Not a fit: Patients with conditions unrelated to immune response or those who do not have access to the necessary treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for cancer and autoimmune diseases.
How similar studies have performed: Previous research has shown promise in using engineered nanoparticles for immunomodulation, indicating a potential for success in this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Green, Jordan — Johns Hopkins University
- Study coordinator: Green, Jordan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.